Juliane Wurm

Juliane Wurm

Auto-generated profile, based on publicly available information

Juliane Wurm

Department of Paediatrics, Fribourg Hospital, Fribourg, Switzerland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
JLJulika Loss
Julika Loss
JWJuliane Wurm
Juliane Wurm
GVGianni Varnaccia
Gianni Varnaccia
ASAnja Schienkiewitz
Anja Schienkiewitz
HIHelena Iwanowski
Helena Iwanowski
SJSusanne Jordan
Susanne Jordan
In daycare centres, the close contact of children with other children and employees favours the transmission of infections. The majority of children <6 years attend daycare programmes in Germany, but the role of daycare centres in the SARS-CoV-2 pandemic is unclear. We investigated the transmission risk in daycare centres and the spread of SARS-CoV-2 to associated households. 30 daycare groups with at least one recent laboratory-confirmed SARS-CoV-2 case were enrolled in the study (10/2020–06/2021). Close contact persons within daycare and households were examined over a 12-day period (repeated SARS-CoV-2 PCR tests, genetic sequencing of viruses, symptom diary). Households were interviewed to gain comprehensive information on each outbreak. We determined primary cases for all daycare groups. The number of secondary cases varied considerably between daycare groups. The pooled secondary attack rate (SAR) across all 30 daycare centres was 9.6%. The SAR tended to be higher when the Alpha variant was detected (15.9% vs. 5.1% with evidence of wild type). The household SAR was 53.3%. Exposed daycare children were less likely to get infected with SARS-CoV-2 than employees (7.7% vs. 15.5%). Containment measures in daycare programmes are critical to reduce SARS-CoV-2 transmission, especially to avoid spread to associated households.

20 March 2024 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
JWJuliane Wurm
Juliane Wurm
AUAnita Uka
Anita Uka
MBMichael Buettcher
Michael Buettcher
LKLisa Kottanattu
Lisa Kottanattu
NSNina Schöbi
Nina Schöbi
OUOn Behalf Of The Swiss Paediatric Surveillance Unit
On Behalf Of The Swiss Paediatric Surveillance Unit
Background: PIMS-TS (pediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2) is a rare but serious condition in children following SARS-CoV-2 infection, characterized by a range of clinical symptoms with varying severity. Understanding risk factors for severe PIMS-TS is crucial for appropriate and timely intervention. Objective: To identify factors associated with increased PIMS-TS severity in children. Methods: In this nationwide prospective observational study, epidemiological and clinical data was collected from children <18 years of age with suspected or confirmed PIMS-TS from all 29 pediatric hospitals in Switzerland. Children were categorized into 3 groups according to admission to intensive care unit (ICU): non-ICU, ICU-moderate and ICU-severe, defined as requirement of invasive ventilation and/or inotropic support. Results: A total of 204 children were included; 99 (49%) were categorized as non-ICU, 50 (25%) as ICU-moderate and 55 (27%) as ICU-severe. In ICU-severe cases, respiratory and neurological symptoms were more frequent compared with non-ICU cases: 72% versus 47%, P < 0.001 and 66% versus 41%, P = 0.001, respectively. Compared with the non-ICU group, children in the ICU-severe group had lower lymphocyte counts, higher neutrophil-lymphocyte ratios, lower platelet counts, as well as higher C-reactive protein, N-terminal pro-B-type natriuretic peptide, troponin T and creatinine levels at admission. Lymphopenia and elevated troponin T levels at admission were associated with an increased risk of being in the ICU-severe group. Conclusion: The severity of PIMS-TS may be predicted using clinical symptoms and laboratory biomarkers, which help clinicians in decision-making and management of patients.

16 December 2023 in Acta Paediatrica
Verified
Journal Article
Open access
JWJuliane Wurm
Juliane Wurm
AUAnita Uka
Anita Uka
VBVera Bernet
Vera Bernet
MBMichael Buettcher
Michael Buettcher
EGEric Giannoni
Eric Giannoni
S(Swiss Paediatric Surveillance Unit (Spsu)
Swiss Paediatric Surveillance Unit (Spsu)
Aim: To investigate the evolution of clinical symptoms of COVID‐19 in children throughout the pandemic.Methods: In this national prospective surveillance study, symptoms in children hospitalised with COVID‐19 were collected from all paediatric hospitals in Switzerland between March 2020 and March 2023. Data was analysed across four time periods, according to the predominantly circulating SARS‐CoV‐2 variant: T1 (wild‐type), T2 (Alpha), T3 (Delta) and T4 (Omicron), as well as by age group.Results: The study included 1323 children. The proportion of children admitted to an intensive care unit remained stable throughout the pandemic. However, the pattern and frequency of clinical manifestations changed over time. Respiratory symptoms were less prevalent during T1 (wild‐type), fever during T2 (Alpha) and rash during T4 (Omicron). In contrast, fever and neurological symptoms were more prevalent during T4 (Omicron). Newly described symptoms during T4 (Omicron) included conjunctivitis, laryngotracheitis and seizures. Fever was more prevalent among neonates and infants whereas respiratory symptoms were more common among infants. Gastrointestinal symptoms were more frequent among toddlers, while both toddlers and school‐aged children presented with neurological symptoms more often than other age groups.Conclusion: Continuous surveillance is required to detect changes in manifestations and there by be prepared for the optimal management of complications in children with COVID‐19.

25 October 2023 in Acta Paediatrica
Verified
Journal Article
Open access
JWJuliane Wurm
Juliane Wurm
BFBianca Finkel
Bianca Finkel
HIHelena Iwanowski
Helena Iwanowski
SJSusanne Jordan
Susanne Jordan
ASAnna Sandoni
Anna Sandoni
JLJulika Loss
Julika Loss

10 June 2026 in BMJ Paediatrics Open
Verified
Journal Article
Open access
JWJuliane Wurm
Juliane Wurm
MBMichael Buettcher
Michael Buettcher
EGEric Giannoni
Eric Giannoni
LKLisa Kottanattu
Lisa Kottanattu
GLGuido F Laube
Guido F Laube
NRNicole Ritz
Nicole Ritz
Background: Although COVID-19 is usually mild in children, antibiotics are frequently prescribed during hospitalisation, often without evidence of bacterial infection. Objective: To assess the frequency and predictors of antibiotic use in children hospitalised with SARS-CoV-2 infection in Switzerland. Methods: In this nationwide prospective study, children aged 0–18 years hospitalised with confirmed SARS-CoV-2 infection or symptoms compatible with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) between January 2022 and March 2023 were included. Univariable and multivariable logistic regression analyses were used to identify risk and protective factors for antibiotic use. A sensitivity analysis was conducted excluding high-risk patients. Results: Among 1944 hospitalised children, 586 (30%) received antibiotics. Of these, 71 (12%) had a clinically suspected bacterial infection without microbiological confirmation and 41 (7%) had microbiologically confirmed infection. Predictors of antibiotic use were microbiologically confirmed bacterial infection (aOR 138.08), clinically suspected bacterial infection (aOR 114.48), haematologic/oncologic disease (aOR 6.77), PIMS-TS (aOR 5.36), fever (aOR 2.98), neonatal age (aOR 2.80) and treatment in tertiary centres (aOR 1.65). After excluding high-risk patients, however, treatment in tertiary centres and PIMS-TS were no longer significant predictors in the sensitivity analysis. Respiratory distress/tachypnoea (aOR 0.72) and admission with confirmed SARS-CoV-2 as the primary diagnosis (aOR 0.42) were associated with lower antibiotic use in the primary analysis. After excluding high-risk patients, this association was no longer observed and nasal symptoms (aOR 0.68) and seizures (aOR 0.34) emerged as protective factors. Conclusion: Antibiotics were frequently prescribed to children hospitalised with SARS-CoV-2 despite limited evidence of bacterial infection. Our findings underscore the need to strengthen antimicrobial stewardship in paediatric COVID-19 care.